Traditional drug discovery is heavily bottlenecked by the slow, iterative process of translating disease insights into viable therapeutic candidates. Here, we are introducing an end-to-end computational pipeline that bridges this gap by unifying artificial intelligence and physics-based simulations to revolutionize biologics discovery. First, we will show how knowledge graphs enable the analysis of complex biological datasets to rapidly identify and validate high-confidence disease targets. Next, we transition to the de novo design phase, demonstrating how generative AI models design custom antibodies, tailored specifically to these target structures. By integrating these AI frameworks with high-precision physics simulations, our platform accurately maps molecular interactions in silico. This enables the rapid generation and optimization of diverse antibody architectures—including Fabs, VHHs, and multi-specific formats—for peak binding affinity and developability. Ultimately, this computational synergy shifts antibody discovery from serendipitous screening to predictable, intelligent design, radically accelerating the journey from target to therapy.